Sera Prognostics कमाई रिजल्ट बराबर, आय चूका Q3 में
- Investing.com
तुलना करने के लिए मीट्रिक्स | SERA | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत औद्योगिक | संबंध संबंधSERAपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −2.4x | −1.5x | −0.2x | |
PEG अनुपात | −0.21 | 0.11 | 0.00 | |
क़ीमत/बुक | 1.5x | 0.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 832.7x | 16.0x | 2.8x | |
अपसाइड (विश्लेषक लक्ष्य) | 148.8% | 168.4% | 65.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 31.1% | 9.6% | अनलॉक करें |
Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.